Floss-based vaccination targets the gingival sulcus for mucosal and systemic immunization
- PMID: 40696115
- DOI: 10.1038/s41551-025-01451-3
Floss-based vaccination targets the gingival sulcus for mucosal and systemic immunization
Abstract
The oral cavity is an accessible site for vaccination, but its sublingual and buccal sites have limited vaccine uptake. Here we show that flat tape dental floss can deliver vaccines through the junctional epithelium of the gingival sulcus, exploiting its naturally leaky properties. Floss-based vaccination delivered protein, inactivated virus, peptide-presenting immunogenic nanoparticles and messenger RNA. In mice, gold nanoparticles functionalized with a peptide derived from the ectodomain of the transmembrane matrix 2 protein of human influenza virus stimulated local lymph nodes, increased CD4+T cells in lymph nodes, lungs and spleen, and boosted antibody-secreting cells in the bone marrow. Floss-based immunization induced strong and sustained immune activation across multiple organs, robust systemic and mucosal antibody responses, and durable protection against lethal influenza infection, independent of age, food and liquid consumption. Floss-based vaccination was superior to sublingual and comparable with intranasal vaccination. In human participants, fluorescent dye delivered via floss picks effectively reached gingival sulcus, supporting clinical feasibility. These findings establish floss-based vaccination as a simple, needle-free strategy that enhances vaccine delivery and immune activation compared with existing mucosal immunization methods.
© 2025. The Author(s), under exclusive licence to Springer Nature Limited.
Conflict of interest statement
Competing interests: H.S.G., R.S.J.I. and A.K.S. are coinventors on a patent related to targeting the JE for vaccination and allergen immunotherapy. H.S.G. and R.S.J.I. are coinventors on a patent related to the pipette-based coating of floss. A startup company is pursuing this technology. This startup company has licensed the patent related to targeting the JE for vaccination and allergen immunotherapy. R.S.J.I. has equity in this company. R.S.J.I. has joined this company by the time the revised version of the paper was submitted. However, findings in this article were not influenced by the company. This potential competing interest has been disclosed and is being managed by TTU. No part of this study was paid for by the company nor was the company involved in any data interpretation or analysis. The other authors declare no competing interests.
References
-
- Deuchert, E. & Brody, S. Lack of autodisable syringe use and health care indicators are associated with high HIV prevalence: an international ecologic analysis. Ann. Epidemiol. 17, 199–207 (2007). - PubMed
-
- Lycke, N. Recent progress in mucosal vaccine development: potential and limitations. Nat. Rev. Immunol. 12, 592–605 (2012). - PubMed
-
- Azzi, L. et al. Mucosal immune response in BNT162b2 COVID-19 vaccine recipients. eBioMedicine 75, 103788 (2022). - PubMed
LinkOut - more resources
Research Materials